Floatz logo

2-methoxyestradiol

Refractory Multiple Myeloma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

498 Active assets in the Refractory Multiple Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

2-methoxyestradiol is also rated in:

Plateau Phase Multiple MyelomaDormant
BB
Indicative ·
64 / 100
View asset →
Recurrent Glioblastoma MultiformeDormant
B
Indicative ·
62 / 100
View asset →
Metastatic Renal Cell CarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →